Bay Area startup Cortexyme gains a $76M round to back a PhII Alzheimer's study, with a new target in their sights
With the evidence increasingly weighing in against amyloid beta as the best solo target for Alzheimer’s, a startup out of San Francisco has identified a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
